A Study of Long-term Administration of Mometasone Furoate Nasal Spray in Pediatric Subjects With Perennial Allergic Rhinitis (Study P06333AM1)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01165424
Recruitment Status : Completed
First Posted : July 19, 2010
Results First Posted : January 23, 2012
Last Update Posted : April 14, 2017
Information provided by (Responsible Party):
Merck Sharp & Dohme Corp.

Brief Summary:
Mometasone furoate nasal spray (MFNS) is a once-a-day product. This is a multi-center, open-label study of MFNS in children with perennial allergic rhinitis. MFNS will be administered to pediatric subjects (3-15 years old) with perennial allergic rhinitis at a dose of 100 to 200 μg/day (once daily) for 12 weeks. Subjects (subject's legal representatives) provided consent to continue treatment beyond 12 weeks will receive treatment for up to 24 weeks. At each clinic visit, observation of adverse events, nasal symptom scores, and nasal findings will be evaluated. The presence/absence of serious adverse events and trial procedure-related AEs will be reviewed 30 days after the end of the follow-up.

Condition or disease Intervention/treatment Phase
Rhinitis, Allergic, Perennial Drug: mometasone furoate Phase 3

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 80 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Study of Long-term (12-24 Weeks) Administration of Mometasone Furoate Nasal Spray in Pediatric Subjects With Perennial Allergic Rhinitis (Protocol No. P06333)
Study Start Date : April 2010
Actual Primary Completion Date : December 2010
Actual Study Completion Date : December 2010

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Arm Intervention/treatment
Experimental: MFNS 50 μg device

MFNS 50 μg spray device. The dose will be as follows:

  • 3 to 11 years: one spray per nostril once daily (100 μg/day) in the morning.
  • 12 to 15 years: 2 sprays per nostril once daily (200 μg/day) in the morning.
Drug: mometasone furoate

MFNS 50 μg spray device

  • 3 to 11 years: one spray per nostril once daily (100 μg/day) in the morning.
  • 12 to 15 years: 2 sprays per nostril once daily (200 μg/day) in the morning.
Other Name: Nasonex

Primary Outcome Measures :
  1. Number of Participants With Adverse Events and Adverse Drug Reactions [ Time Frame: Baseline to Week 24 ]

Secondary Outcome Measures :
  1. Change From Baseline in the Total Nasal Symptom Score [ Time Frame: Baseline and Weeks 2, 4, 8, 12, and 24 (or discontinuation) ]
    Total nasal symptom score was a composite of 4 symptoms (sneezing, rhinorrhea, nasal congestion, and nasal itching). Each symptom was scored on a scale of 0 = none, 1 = mild, 2 = moderate, and 3 = severe for a total score ranging from 0 to 12. A higher score indicates more severe symptoms.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   3 Years to 15 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Subjects having symptoms of perennial allergic rhinitis of moderate to severe degree.
  • Subjects confirmed to be allergic to non-seasonal environmental antigens (e.g., house dust mite antigen).
  • Male or female outpatients aged 3 to 15 years at the time of providing informed consent.

Exclusion Criteria:

  • Subjects with coexisting tuberculosis or lower respiratory tract infection, or who have an acute upper respiratory tract infection or acute pharyngolaryngitis, etc. judged by the investigator to require treatment at the time of registration
  • Subjects with coexisting infections or systemic mycosis for which there are no effective antibiotics
  • Subjects with repeated epistaxis
  • Subjects with coexisting fungal infection in nasal/sinus cavity
  • Subjects with a history of hypersensitivity to steroids or ingredients of mometasone furoate nasal spray
  • Subjects with severe hepatic, renal, cardiac, hematological disease, diabetes mellitus, hypertension, or other serious coexisting diseases and whose general condition is poor.
  • Subjects allergic to pollen (cedar, Japanese cypress, birch, grasses, mugwort, common ragweed, etc.) for whom the pollen season coincides with the observation period

Responsible Party: Merck Sharp & Dohme Corp. Identifier: NCT01165424     History of Changes
Other Study ID Numbers: P06333
First Posted: July 19, 2010    Key Record Dates
Results First Posted: January 23, 2012
Last Update Posted: April 14, 2017
Last Verified: March 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description:

Additional relevant MeSH terms:
Rhinitis, Allergic
Rhinitis, Allergic, Perennial
Nose Diseases
Respiratory Tract Diseases
Respiratory Tract Infections
Otorhinolaryngologic Diseases
Respiratory Hypersensitivity
Hypersensitivity, Immediate
Immune System Diseases
Mometasone Furoate
Anti-Inflammatory Agents
Dermatologic Agents
Anti-Allergic Agents